A clinical utility study claimed use of the Afirma Gene Expression Classifier, developed by Veracyte Inc., can significantly reduce unnecessary surgeries in thyroid cancer diagnoses. The study was published in Cancer Cytopathology.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
